Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Whoever's closest to the consumer will be the gatekeeper of the industry.

Principal, Health & Life Sciences, Organizational Effectiveness, Oliver Wyman
Principal, Oliver Wyman
Senior Consultant, Oliver Wyman

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health & Life Sciences, Oliver Wyman
Senior Knowledge Expert, Health & Life Sciences, Oliver Wyman

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Principal, Health & Life Sciences, Oliver Wyman

Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.

Insights in your inbox

Subscribe

How pharmaceutical companies can better define, measure, and deliver value to patients.

Principal, Health & Life Sciences, Oliver Wyman
Associate, Health & Life Sciences, Oliver Wyman

What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.

Senior Managing Director, GE Ventures

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

How a “sticky” consumer experience could help control the drain of high-cost chronic disease drugs.

Partner, Health & Life Sciences, Oliver Wyman

Direct-purchase agreements are being floated as a price-control strategy. But how is value defined? And when might low cost come at the expense of true value?

Partner, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

Insights in your inbox

Subscribe